Cost-effectiveness of patch testing allergens within the same group: A computational approach to optimize formaldehyde-related allergen selection - 18/10/24
Abstract |
Background |
Patch testing for multiple cross-reactive allergens for allergic contact dermatitis (ACD) may not be necessary because of copositivity.
Objectives |
We evaluated the formaldehyde group allergens to determine the optimal, most cost-effective allergens to test.
Methods |
A retrospective analysis of Mayo Clinic (1997-2022) examined the well-established copositive formaldehyde group: formaldehyde, quaternium 15, hexahydro-1,3,5-tris(2-hydroxyethyl)triazine, diazolidinyl urea, imidazolidinyl urea, toluenesulphonamide formaldehyde resin, DMDM hydantoin, and ethyleneurea melamine formaldehyde mix. Patch Optimization Platform identified which single formaldehyde-related allergen optimally captures patients with clinically relevant ACD. Next, Patch Optimization Platform determined the optimal additional 1, 2, 3, etc. allergens. Cost per patch test was $5.19 (Medicare 2022).
Results |
A total of 9832 patients were tested for all listed allergens, with 830 having positive patch test results. Patch Optimization Platform determined that quaternium 15 alone captures 53% of patients with ACD to the formaldehyde group; adding the optimal second allergen (formaldehyde 1%) captures 78%; the optimal 5 top allergens capture >94% of patients. The incremental cost per additional diagnosis increased up to 44-fold as the number of allergens tested increased.
Limitations |
Data are from a single institution, and the cost per test was fixed according to Medicare Part B in 2022.
Conclusions |
For diagnosing ACD, we recommend considering an optimized allergen selection algorithm.
Le texte complet de cet article est disponible en PDF.Key words : contact dermatitis, copositivity, coreactivity, cross-reactivity, formaldehyde, patch testing
Abbreviations used : ACD, ACDS, Aq, NACDG, POP, TRUE
Plan
| Funding sources: Supported by the Kathryn H. and Roger Penske Career Development Award to Support Medical Research at Mayo Clinic Arizona (Y.W.Y.). |
|
| IRB approval status: Exempt. |
Vol 91 - N° 5
P. 843-847 - novembre 2024 Retour au numéro
Article précédent
- Assessment of diagnostic delay, morbidity, and mortality outcomes in 302 calciphylaxis patients over a 17-year period: A retrospective cohort study
- Alice J. Tan, Joyce Xia, Colleen M. Glennon, Joseph J. Locascio, Colleen K. Gabel, Emily D. Nguyen, Sidharth Chand, Renajd Rrapi, Allison S. Dobry, Anna Cristina Garza-Mayers, Lauren N. Ko, Radhika Shah, Jessica St John, Sagar U. Nigwekar, Daniela Kroshinsky
- Optical coherence tomography-measured blood vessel characteristics of port-wine birthmarks by depth: A cross-sectional study
- Rachel Ann Elsanadi, Feben Messele, Jaylen Lee, Bernard Choi, Kristen M. Kelly
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?